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Available online at www.sciencedirect.comMalaria remains the world’s most prevalent human parasitic
disease. Because of the rapid spread of drug resistance in
parasites, there is an urgent need to identify diverse new drug
targets. One group of proteases that are emerging as targets
for novel antimalarials are the metalloaminopeptidases. These
enzymes catalyze the removal of the N-terminal amino acids
from proteins and peptides. Given the restricted specificities of
each of these enzymes for different N-terminal amino acids, it is
thought that they act in concert to facilitate protein turnover.
Here we review recent structure and functional data relating to
the development of the Plasmodium falciparum
metalloaminopeptidases as drug targets
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Introduction
The metalloaminopeptidases (MAPs) constitute a diverse
set of protease enzymes with essential roles in cell main-
tenance, growth and development, and defense. Their
active sites coordinate essential metal ion(s) that activate
a water molecule to form an hydroxide nucleophile which
attacks the scissile peptide bond, releasing the P1 pos-
ition amino acid1 [1]. The aminopeptidases are classified
into families based on structural patterns and substrate
specificity in particular by the preference shown for
specific amino acids at the P1 position [2].
Open access under CC BY-NC-ND license.1 The nomenclature of Schechter and Berger [1] is used here. P1 and
P10 refer to substrate residues while the S1, S10 refer to the correspond-
ing enzyme subsites.
Current Opinion in Structural Biology 2013, 23:828–835 Parasites of the genus Plasmodium are the causative agents
of malaria. While four Plasmodium species commonly infect
humans, Plasmodium falciparum (Pf) causes the most
deaths [3–5]. To date, nine MAPs have been identified
in Pf (3D7) [6]. Four of these are methionine aminopepti-
dases. The other five enzymes comprise a prolyl imino-
peptidase (or post-prolyl aminopeptidase),2 a prolyl
aminopeptidase (see footnote 2), a leucine aminopepti-
dase, an alanine aminopeptidase and an aspartyl amino-
peptidase. Given the restricted specificities of each of
these enzymes for particular N-terminal amino acids, it
is thought that they act in concert to facilitate hemoglobin
(Hb) catabolism [7,8], a process essential to the survival of
Pf. However, recent studies show that the PfMAPs may
have additional roles to that of Hb digestion, including
important housekeeping functions and in conjunction with
the parasite proteosome [9,10]. The essential nature of
the PfMAP activity has sparked interest in using them as
targets for the development of novel antimalarials [11,12].
Drug campaigns have successfully targeted proteases; for
example, the angiotensin-converting enzymes (hypoten-
sion drugs including the original Captopril, Bristol Myers
Squibb) and HIV protease (HIV/AIDs anti-retrovirals
including the original Saquinavir, Hoffman-La Roche).
However, developing drugs for new protease targets has
proven to be particularly challenging, in part due to the
importance of achieving selectivity [13]. Since the para-
site and host MAPs show limited sequence identity
(<35%) and have differing substrate specificities, rational
design and delivery of selective parasite-specific inhibi-
tors is an exciting possibility. A general approach for
therapeutically targeting proteases is to identify specific
inhibitors — generally small molecules — that can block
the active site. The search for inhibitors can be acceler-
ated with knowledge of both the active site structure and
the intrinsic subsite occupancy. If rational drug design
platforms are going to succeed, it will be absolutely
essential that precise structure–activity-relationship and
mechanistic data are available that can be used to exploit
selective intricacies of the parasite enzyme over its mam-
malian homologs.
The methionine aminopeptidases
The methionine aminopeptidases (MetAP) perform the
essential housekeeping role of catalyzing the removal of2 To date, there is no structural information for either prolyl amino-
peptidase and as such, these two proteases will not be discussed further
in this review.
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thesis [14]. Two distinct types of MetAP enzymes exist,
MetAP1 and MetAP2, having mutually redundant yet
essential functions within all organisms [15]. In compari-
son to MetAP1, MetAP2 has a 65 amino acid insertion in
its catalytic domain and an additional N-terminal domain
(in eukaryotes) [14]. The PfMetAP2 enzyme contains a
274 residue N-terminal domain and a conserved catalytic
C-terminal domain [16] (Figure 1a). Recombinant PfMe-
tAP2 binds fumagillin derivatives with high selectivityFigure 1
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The structure of the PfMetAPs. (a) The domain structure of the
PfMetAPs. The three isoforms of PfMetAP1 all contain a canonical
MetAP1 catalytic domain (shown in ruby). PfMetAP1c contains an N-
terminal signal peptide (in blue, SP) followed by a transit peptide domain
(in green, T) to target the enzyme to the apicoplast [16]. PfMetAP1c also
contains a 210 residue insertion in the MetAP1 catalytic domain
(shown as black line). The PfMetAP2 enzyme has a 274 residue N-
terminal extension (in green, NTE) before a canonical MetAP2 domain.
(b) The 1.95 A˚ X-ray crystal structure of PfMetAP1b shows a canonical
MetAP1 fold (in ruby) (3S6B, MolProbity Quality Score 1.42 = 97th
percentile). The PfMetAP1b enzyme has an N-terminal extension of 56
amino acids when compared to the human enzyme representatives (in
gray in a and b), extra 10 unstructured amino acids at its C-terminus (in
gray). A single FeIII ion (orange sphere) is coordinated by residues H270,
E303 and E334 (shown in sticks). A water molecule (light blue sphere) is
located in the second metal site in other MetAP1 structures and is
coordinated by conserved active site residues D193 and D204 (shown in
sticks). The water molecule contributes to an apparent pentavalent
coordination of the FeIII ion (metal bonds shown as black dashes).
www.sciencedirect.com and these compounds are now being considered as anti-
malarial agents targeting PfMetAP2 [16].
There are three isoforms of MetAP1 in Pf ; PfMetAP1a,
PfMetAP1b and PfMetAP1c [6] (Figure 1a). The three
MetAP1 isoforms are active and have comparable activi-
ties to other members of the mammalian MetAP1 family
[17]. PfMetAP1a contains the minimal catalytic domain
and PfMetAP1c has a signal peptide in its longer N-
terminal for targeting the enzyme to the apicoplast [16]
(Figure 1a). PfMetAP1b is the most characterized of the
three MetAP1s. It is expressed in the early intra-erythro-
cytic stage of the Pf lifecycle [18]. Inhibition of PfMe-
tAP1b with the highly selective compound XC11 that
contains a 2-(2-pyridinyl)-pyrimidine core resulted in
inhibition of Pf proliferation in vitro and was active in
mouse malaria models that included drug-resistant Pf
strains [17]. It has been suggested that PfMetAP1b is a
promising target for the development of novel antimalar-
ial drugs [17]. There are currently no published structures
of the PfMetAPs; however, the Structural Genomics
Consortium solved the structure of PfMetAP1b, the
target of the antimalarial XC11 compound (3S6B, depos-
ited RCSB 2011). The structure shows a typical MetAP1
core fold of pseudo twofold-related N-terminal and C-
terminal domains, containing two a-helices and two anti-
parallel b-strands (Figure 1b). Unlike characterized mam-
malian homologs, the PfMetAP1b active site contains a
single FeIII ion rather than a di-metal core. The bio-
logical relevance of this difference remains unknown.
Structural alignment of 3S6B with other known MetAP1
folds identifies the human MetAP1b as the closest struc-
tural homolog (and 4FLI the closest structural homolog)
[19]. Structural alignment of the human enzyme with
PfMetAP1b identifies that the FeIII ion in PfMetAP1b is
equivalent to one metal ion site present in the human
MetAP1 structures and that a water molecule occupies
the second metal site (Figure 1b).
The M1 alanyl aminopeptidase, PfA-M1
The PfA-M1 alanyl aminopeptidase enzyme is responsible
for the final stages of hemoglobin (Hb) digestion [9], a
process that provides a source of amino acids for incorp-
oration into parasite proteins [20–22]. The PfA-M1
enzyme has a broad specificity for the P1 amino acid
and includes most basic and hydrophobic amino acids
[23,24,25] but preferentially cleaves leucine and meth-
ionine [25]. PfA-M1 also has subsite specificity require-
ments for activity [26]. Engagement of the S1, S10 and S20
subsites can contribute to the catalytic efficiency [26].
Proteolytic activity of PfA-M1 has been identified in both
the parasitic cytosol and the digestive vacuole, the mem-
brane vesicle where Hb digestion begins [7,9,23,24,27].
Whether PfA-M1 digests Hb peptides in the digestive
vacuole or the cell cytosol has been the topic of debate
[7,9,23,24,27–29,30]. The PfA-M1 enzyme shows a
100-fold decrease (kcat/Km) in overall efficiency in an acidicCurrent Opinion in Structural Biology 2013, 23:828–835
830 Catalysis and regulationpH (representing the digestive vacuole environment),
arguing for a cytosolic function [23,24,29,31]. However,
specific inhibition of the enzyme results in a change in the
digestive vacuole morphology [9] and Ragheb et al. [30]
convincingly argue that, although the enzyme is less effi-
cient at the vacuole pH (acidic), the high concentration of
Hb peptide substrates (low mM in the vacuole) drives the
substrate binding to PfA-M1 and leads to sufficient amino-
peptidase activity [30].
PfA-M1 is encoded on a single gene that encodes a
monomeric protein of 1085 amino acids in length
(122 kDa) [23,31]. The full length species possesses a
unique 196 amino acid N-terminal extension that is
removed to form the proteolytically active form of the
protein (103 kDa) [23,24,27,30]. This proteolytically
active species is processed to a stable complex of 68 and
35 kDa fragments [30] and argues against the existenceFigure 2
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enzymes can therefore influence the catalytic efficiency against peptide subs
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antiplasmodial activity against drug resistance strains of malaria [38,40].
Current Opinion in Structural Biology 2013, 23:828–835 of an active isoform of only 68 kDa that was reported earlier
[31]. Further, recombinant work using PfA-M1 supports
the propensity for cleavage, creating two fragments that
remain tightly associated ([24] and McGowan unpub-
lished). A nuclear species of PfA-M1 has also been ident-
ified; however, its role in the parasite nucleus remains
unknown [30]. The N-terminal extension of the protease
has been shown to contribute to the targeting and distri-
bution of PfA-M1 in the parasite [30].
Inhibition of PfA-M1 results in antiplasmodial activity
[32–34] and as such is considered an attractive candidate
to initiate screening and lead optimization in a search for
novel antimalarial agents. To date, inhibitors of PfA-M1
have targeted the active site of the enzyme and recent
inhibitor scaffolds described include phosphonopeptides
[24,25,33], peptide-based bestatin and analogs
[9,24,35,36], and hydroxamate derivatives [37,38].E461
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ecent dual inhibitors of the two enzymes. PfA-M1 (a) adopts a canonical
lored by domain). A simplified domain architecture with residue numbers
s located in domain II and is completely buried within the protein’s core
(shown as black sphere, inset a) and is coordinated by a classic catalytic
 yellow) in its unbound form. Short molecular dynamic simulations of the
zyme uses a two-step catalytic mechanism, in which the conformation of
te [50]. PfA-M17 is a biological homohexamer and is shown as a cartoon
n (N-terminal domain shown in green) and a C-terminal catalytic domain
P) family fold [51]. A helical linker connects the N-terminal and C-terminal
omain boundaries is shown underneath cartoon model. The active site of
(site 1) and a tight binding site (site 2) [44,45]. The LAP enzyme family
wn as sticks, inset b). The metal ions are coordinated by residues K374,
tion binding at site 1 of PfA-M17 can be functionally exchanged for other
> Co2+ > Mg2+ [45]. The type of metal cation in the active site of these
trates as well as the binding of inhibitors. The X-ray crystal structures of
tes. Two potent inhibitors of the enzymes, Bestatin and hPheP[CH2]Phe,
4,44]. The two inhibitors, CHR-2863 and BDM14471, have both shown
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The X-ray crystal structure of PfM18AAP reveals a dodecameric
assembly. The model of PfM18AAP is shown as a space-filled molecule,
except for chain A which is shown as cartoon. The molecule is colored
by chain and not all 12 chains are visible in this view. Each PfM18AAP
monomer (chain A is shown as cartoon to show detail of monomer)
contains two domains — one predominantly used for protein-protein
interactions (in cyan, regulatory domain) and a second catalytic domain
(in magenta, Figure 4). Together the two domains adopt a typical
aspartyl aminopeptidase fold [46]. A simplified domain architecture
with residue numbers of domain boundaries is shown underneath
cartoon model. Three PfM18AAP catalytic domains interact to form a
cone-shaped trimer and regulatory domains act as packing buffers
between the trimer of catalytic domains. The dodecameric enzyme is
built from the interactions of four PfM18AAP trimers with an interior
active site cavity of M18 comprising four trimer cones, each with their
three active sites [46]. The active site of PfM18AAP also has a di-cation
core as shown in the inset (zinc ions shown as black spheres) and the
metals are coordinated by residues H87, D325, E381, D435 and H535
(shown as sticks, inset).The active site of PfA-M1 contains a single catalytic zinc
ion (Figure 2). The inhibitor scaffolds all act to chelate
the zinc ion and mimic the transition state of the
molecule. Targeting the zinc ion using phosphonopep-
tides and bestatin derivatives produced potent inhibitors
of the enzyme [9,24,32,33,36]; however, creating a
parasite specific inhibitor is likely to require the engage-
ment of specific elements of the PfA-M1 architecture. Like
many proteases, PfA-M1 has an ability to accommodate
organic molecules even when its active site is buried within
a large protein. Velmouragane et al. showed that the S1
pocket is capable of substantial inhibitor-induced re-
arrangement due to the presence of a flexible polar glu-
tamic acid (Glu572) in the pocket [36]. One of the best
cleaved P1 residues is Arg or homoArg [25] and recent
work has shown that derivatives of these amino acids are
also able to induce changes in the backbone position of S1
pocket that are not associated with Glu572 [39].
The cellular location of the PfA-M1 enzyme also
represents significant challenges for drug design and
delivery; however, recent advances show that compounds
can be delivered and reach the site of action. An orally
bioavailable hydroxamate-containing ester, CHR-2863,
has been shown to be efficacious against murine malaria
(Plasmodium chaubaudi) [40]. The compound is, however,
a close relative of Tosedostat, a potent inhibitor of a
number of intracellular mammalian aminopeptidases.
The authors conclude that CHR-2863 still requires
toxicity testing but represents an important step forward
in showing that the PfMAPs can be targeted by oral
administration of inhibitors [40]. In a separate study, a
malono-hydroxamic lead compound [37], with good phy-
sicochemical properties, in vitro plasma stability and
promising antiplasmodial activity in vitro, was assessed
in mice using the malaria strain Plasmodium berghei [38].
The in vivo results did not match the potency noted in
vitro and Deprez-Poulain et al., then assessed the plasma
concentration and distribution of BDM14471 after a
single dose in mice [38]. The results showed that the
compound was capable of penetrating the erythrocyte,
indicating that this was not the cause of the gap between
the in vitro and in vivo results. The authors suggested,
given these results that the proteolytic activity of PfA-M1
is not critical for survival of intra-erythrocytic parasites,
but does concede that the compound may be trapped in
the red blood cell and not actually enter the parasite
[38]. A further question, not highlighted in the article, is
whether the compound can penetrate the digestive
vacuole where the proteolytic activity of PfA-M1 is
thought to predominate [9].
The leucyl aminopeptidase, PfA-M17
The leucyl Aminopeptidase PfA-M17 is postulated to be
involved in the Hb digestion pathway, generating free
amino acids at the final stages of this process [41]. How-
ever, in contrast to PfA-M1, PfA-M17 may havewww.sciencedirect.com additional function(s) since specific inhibition of its
activity in Pf parasite cultures causes growth retardation
early in the intra-erythrocytic life cycle before Hb diges-
tion is initiated [8,9].
PfA-M17 possesses a severely restricted specificity for N-
terminally exposed bulky, hydrophobic amino acids
[25] and a preference for leucine [41]. A similar sub-
strate and biochemical profile was obtained when the
M17 aminopeptidase from Plasmodium vivax was charac-
terized [42]. A possible explanation for the essential role
of the PfA-M17 (and indeed PfA-M1) is that, in addition
to regulating the general intracellular pool of amino acids,
both PfA-M1 and PfA-M17 are critical in the hydrolysis of
dipeptides that release free leucine. The only amino acidCurrent Opinion in Structural Biology 2013, 23:828–835
832 Catalysis and regulationnot found in human Hb and which cannot be synthesized
by the parasite is isoleucine. This amino acid must be
obtained from the external environment [20]. The uptake
of isoleucine by parasites is mediated by a two-step
process involving an ATP-independent transported
capable of exchanging intra-cellular leucine for isoleu-
cine, and the ATP-dependent storage or accumulation of
this amino acid within parasites [43].
The PfA-M17 enzyme forms a functional homohexamer
[41,44]. The X-ray crystal structure of the M17 revealed
the complex detail of the biological hexamer (Figure 3)
[44]. PfA-M17 uses self-association to restrict access to
its active sites and as such proteolysis is subject to spatial
and temporal control. Access to the enclosed active-site
cavity has been hypothesized to occur via channels
formed by the N-terminal domains of each monomer
[44]. Each PfA-M17 active site contains two metal-
binding sites, a readily exchangeable site (site 1) and aFigure 4
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Current Opinion in Structural Biology 2013, 23:828–835 tight binding site (site 2) [45]. While M17 retains residual
catalytic activity when the metal ion from site 1 is
removed, the removal of metal ions from both sites results
in an inactive apo-enzyme that cannot be re-activated by
addition of divalent metal cations [45].
The aspartyl aminopeptidase, PfM18AAP
Despite annotation as an aspartyl aminopeptidase, the
PfM18AAP enzyme has highly restricted specificity for
glutamate as well as aspartate [46,47] and reduced
activity against asparagine [46]. The precise role of
PfM18AAP in Pf remains unknown and will require potent
and specific inhibitors/activity-based probes to identify its
function in vivo. Gene disruption/truncation experiments
of PfM18AAP indicated that the enzyme was dispensable
for blood-stage replication but had an associated fitness
cost to the parasite [7]. Anti-sense RNA knockdown of
PfM18AAP, however, resulted in parasite growth abnorm-
alities, vascularization, and cellular damage [47]. TheD
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suggest that, like PfA-M17, PfM18AAP may also have
important functions in addition to Hb digestion [10,47].
The biological assembly of the PfM18AAP is a dodeca-
mer that forms a tetrahedron shape (Figure 3) in a similar
arrangement to the M42 glutamyl aminopeptidases [48].
PfM18AAP shares only 34% identity with the human
enzyme and contains a large insertion of 65 amino in
the regulatory domain that is unique to the Pf enzyme (it
is not present in other Plasmodium M18 enzymes that
share > 75% identity). The role of this unique insertion
remains unknown [10,46,47]. The location of this loop
indicates that it may act as a sentinel, guarding the pore
entry to the inner active site cavity (Figure 3). PfM18AAP
thus resembles a proteasomal-like machine with multiple
active sites able to degrade peptide substrates that enter
the central lumen [46]. Each active site contains two
well-coordinated zinc ions [46]. The active site of each
monomer is a small closed cavity that has a small entrance
(diameter 5.6 A˚) [46]. Studies using chelation agents
have shown that altering the type of metal ion can
increase catalytic efficiency but does not affect binding
of the substrate [47]. To date, no potent inhibitors of
PfM18AAP have been published; however, a high-
throughput screening approach has been undertaken
and results of this bioassay are publically available from
the PubChem BioAssay.
Conclusions and outlook
The artemisinin-based combination therapies (ACTs) are
the current regime for malaria and have been deployed
globally with tremendous success for over a decade.
Recent reports, however, of the emergence of resistance
to the artemisinins in South-East Asia is alarming. Should
the ACTs fail, no suitable first-line treatments are avail-
able for Pf malaria [49]. The PfMAPs have essential
biological functions in Pf (Figure 4) and represent attrac-
tive targets for the development of novel antimalarial
agents. Similarities between different classes of enzyme
raise the possibility of designing combination inhibi-
tors — one compound to target one or more PfMAPs,
thus slowing the emergence of drug resistant parasites.
The PfA-M1 and PfA-M17 enzymes show promise in this
regard. To overcome the many challenges of producing
drugs against the PfMAPs, a simultaneous dual approach
will be necessary. Our understanding of the biological role
that the enzymes fulfill within the parasite lifecycle is
absolutely pivotal to success as are the initial compound
discovery campaigns to identify, test, optimize and
develop potent inhibitors that can be used in downstream
drug development.
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